COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,357 Articles (22,803 medRxiv, 8,554 bioRxiv)

Most recent first Previous |  Page 359: Articles 3581-3590  | Next

The potential clinical impact and cost-effectiveness of the updated COVID-19 mRNA Fall 2023 vaccines in the United States
Kohli, M., Maschio, M., Joshi, K., Lee, A., Fust, K., Beck, E., Van de Velde, N., Weinstein, M. C.
10.1101/2023.09.05.23295085 — Posted: 2023-09-07
The anti-SARS-CoV-2 BNT162b2 vaccine suppresses mithramycin-induced erythroid differentiation and expression of embryo-fetal globin genes in human erythroleukemia K562 cells
Zurlo, M., Gasparello, J., Verona, M., Papi, C., Cosenza, L. C., Finotti, A., Marzaro, G., Gambari, R.
10.1101/2023.09.07.556634 — Posted: 2023-09-07
SARS-CoV-2 ORF7a mutation found in BF.5 and BF.7 sublineages impacts its functions
Timilsina, U., Duffy, S., Plianchaisuk, A., Ito, J., Sato, K., Stavrou, S.
10.1101/2023.09.06.556547 — Posted: 2023-09-07
Transmissibility, infectivity, and immune resistance of the SARS-CoV-2 BA.2.86 variant
Uriu, K., Ito, J., Kosugi, Y., Tanaka, Y. L., Mugita, Y., Guo, Z., Hinay, A. A., Putri, O., Kim, Y., Shimizu, R., Begum, M. M., Jonathan, M., The Genotype to Phenotype Japan (G2P-Japan) Consortium, , Saito, A., Ikeda, T., Sato, K.
10.1101/2023.09.07.556636 — Posted: 2023-09-07
The molecular reach of antibodies determines their SARS-CoV-2 neutralisation potency
Huhn, A., Nissley, D. A., Wilson, D. B., Kutuzov, M. A., Donat, R., Tan, T. K., Zhang, Y., Barton, M. I., Liu, C., Dejnirattisai, W., Supasa, P., Mongkolsapaya, J., Townsend, A., James, W. S., Screaton, G., van der Merwe, P. A., Deane, C., Isaacson, S., Dushek, O.
10.1101/2023.09.06.556503 — Posted: 2023-09-07
Convergent Sequence Features of Antiviral B Cells
Abu-Shmais, A. A., Vukovich, M. J., Wasdin, P. T., Suresh, Y. P., Rush, S. A., Gillespie, R. A., Sankhala, R. S., Choe, M., Joyce, M. G., Kanekiyo, M., McLellan, J. S., Georgiev, I. S.
10.1101/2023.09.06.556442 — Posted: 2023-09-07
Immunogenicity and tolerability of a SARS-CoV-2 TNX-1800, a live recombinant poxvirus vaccine candidate, in Syrian Hamsters and New Zealand White Rabbits.
Awasthi, M., Macaluso, A., Goebel, S. J., Luea, E., Noyce, R. S., Nasar, F., Daugherty, B., Bavari, S., Lederman, S.
10.1101/2023.09.06.556620 — Posted: 2023-09-07
Safety and immunogenicity of VLPCOV-02, a SARS-CoV-2 self-amplifying RNA vaccine with a modified base, 5-methylcytosine, in healthy individuals
Aboshi, M., Matsuda, K., Kawakami, D., Kono, K., Kazami, Y., Sekida, T., Komori, M., Morey, A. L., Suga, S., Smith, J. F., Fukuhara, T., Iwatani, Y., Yamamoto, T., Sato, N., Akahata, W.
10.1101/2023.09.04.23294493 — Posted: 2023-09-06
Serological outcomes of SARS-CoV-2 infection by vaccination status and variant in England
Quinot, C., Lunt, R., Kirsebom, F., Andrews, N., Whitaker, H., Skarnes, C., Letley, L., Haskins, D., Angel, C., Firminger, S., Ratcliffe, K., Sheridan, A., Rajan, S., Akindele, L., Ijaz, S., Zambon, M., Brown, K., Ramsay, M., Lopez Bernal, J.
10.1101/2023.09.05.23295073 — Posted: 2023-09-06
IMPACT OF THE COVID-19 PANDEMIC ON ROUTINE HIV CARE AND ANTIRETROVIRAL TREATMENT OUTCOMES IN KENYA: A NATIONALLY REPRESENTATIVE ANALYSIS
Kimanga, D. O., Makory, V. N. B., Hassan, A. S., Ngari, F., Ndisha, M. M., Muthoka, K. J., Odero, L., Omoro, G. O., Aoko, A., Ng'ang'a, L.
10.1101/2023.09.04.23294973 — Posted: 2023-09-06

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).